Routes of
administration Oral Legal status Investigational CAS Number 165538-40-9 Molar mass 407.911 g/mol | ATC code none Biological half-life 6–10 hours PubChem CID 9938840 | |
 | ||
How to pronounce terutroban
Terutroban is an antiplatelet agent developed by Servier Laboratories. It has been tested for the secondary prevention of acute thrombotic complications in the Phase III clinical trial PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack). The study was prematurely stopped and thus it could not be determined whether terutroban has a better effect than aspirin.
Contents
Method of action
Terutroban is a selective antagonist of the thromboxane receptor. It blocks thromboxane induced platelet aggregation and vasoconstriction.
References
Terutroban Wikipedia(Text) CC BY-SA